Nobuyuki Katakami

16.9k total citations · 1 hit paper
216 papers, 6.4k citations indexed

About

Nobuyuki Katakami is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Nobuyuki Katakami has authored 216 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 160 papers in Pulmonary and Respiratory Medicine, 151 papers in Oncology and 29 papers in Surgery. Recurrent topics in Nobuyuki Katakami's work include Lung Cancer Treatments and Mutations (134 papers), Lung Cancer Research Studies (85 papers) and Lung Cancer Diagnosis and Treatment (57 papers). Nobuyuki Katakami is often cited by papers focused on Lung Cancer Treatments and Mutations (134 papers), Lung Cancer Research Studies (85 papers) and Lung Cancer Diagnosis and Treatment (57 papers). Nobuyuki Katakami collaborates with scholars based in Japan, United States and Italy. Nobuyuki Katakami's co-authors include Akito Hata, Shunichi Negoro, Keisuke Tomii, Koji Takeda, Masahiro Fukuoka, Kazuhiko Nakagawa, Toyoaki Hida, Shiro Fujita, Nobuyuki Yamamoto and Reiko Kaji and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Nobuyuki Katakami

206 papers receiving 6.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)

2018 349 citations Yi‐Long Wu, Myung‐Ju Ahn et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Nobuyuki Katakami

Since Specialization

Citations

This map shows the geographic impact of Nobuyuki Katakami's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nobuyuki Katakami with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nobuyuki Katakami more than expected).

Fields of papers citing papers by Nobuyuki Katakami

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nobuyuki Katakami. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nobuyuki Katakami. The network helps show where Nobuyuki Katakami may publish in the future.

Co-authorship network of co-authors of Nobuyuki Katakami

This figure shows the co-authorship network connecting the top 25 collaborators of Nobuyuki Katakami. A scholar is included among the top collaborators of Nobuyuki Katakami based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nobuyuki Katakami. Nobuyuki Katakami is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	BEAT-SC: A randomized phase III study of bevacizumab or placebo in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC). 2024 ·Journal of Clinical Oncology ·Yuichiro Ohe, (unknown), (unknown), Satoshi Watanabe, Xiubao Ren, Shuji Murakami, Nong Yang, Isamu Okamoto, (unknown), Nobuyuki Katakami, (unknown), Naoyuki Nogami, (unknown), (unknown), Toshihiro Nanki, (unknown), Nobuyuki Yamamoto	15
2	Radiation therapy (RT)-free pembrolizumab plus chemotherapy (P+C) for PD-L1 TPS ≥50% locally advanced non-small cell lung cancer (LA-NSCLC): Primary analysis from multicenter single arm phase II study (Evolution trial; WJOG11819L). 2024 ·Journal of Clinical Oncology ·Akito Hata, (unknown), (unknown), Yoshihito Kogure, Masahide Oki, Nobuyuki Katakami, Takashi Kijima, Toshihide Yokoyama, Hirotaka Matsumoto, Yuki Sato, Terufumi Kato, Shunichi Sugawara, Takeshi Sawada, Kenichi Yoshimura, Takashi Seto, Kazuhiko Nakagawa, (unknown), Nobuyuki Yamamoto	0
3	Randomized phase II study of zoledronate dosing every four versus eight weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312) 2023 ·Lung Cancer ·Nobuyuki Katakami, Takashi Nishimura, (unknown), Akito Hata, Kazumi Nishino, Masahide Mori, Tomonori Hirashima, (unknown), Toshihiko Kaneda, Hisashi Ohnishi, Satoshi Morita, Yukimasa Hatachi	2
4	Phase Ib Study of Osimertinib Plus Ramucirumab in Japanese Lung Cancer Patients With EGFR Mutation 2021 ·Anticancer Research ·Hiroaki Akamatsu, Yuichi Ozawa, Jun Oyanagi, Daichi Fujimoto, Akito Hata, Nobuyuki Katakami, Keisuke Tomii, Eriko Murakami, (unknown), Toshio Shimokawa, Yasuhiro Koh, Nobuyuki Yamamoto	4
5	Successful Treatment of a Mixed Neuroendocrine-Nonneuroendocrine Neoplasm of the Colon with Metastases to the Thyroid Gland and Liver 2020 ·SHILAP Revista de lepidopterología ·Yuji Kanazawa, Masahiro Kikuchi, Yukihiro Imai, Nobuyuki Katakami, Satoshi Kaihara, Shogo Shinohara	9
6	<p>A multi-center, Phase II trial of nab-paclitaxel and gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy</p> 2019 ·Cancer Management and Research ·Motoko Tachihara, Tatsunori Kiriu, Akito Hata, (unknown), Kyosuke Nakata, Tatsuya Nagano, Masatsugu Yamamoto, Kazuyuki Kobayashi, Hisashi Ohnishi, Nobuyuki Katakami, Yoshihiro Nishimura	5
7	Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer 2019 ·Cancer Science ·Shinji Takeuchi, Tetsunari Hase, Shinobu Shimizu, Masahiko Ando, Akito Hata, Haruyasu Murakami, Takahiro Kawakami, (unknown), Kenichi Yoshimura, T. Fujiwara, Azusa Tanimoto, Akihiro Nishiyama, Sachiko Arai, Koji Fukuda, Nobuyuki Katakami, Toshiaki Takahashi, Yoshinori Hasegawa, Tun Kiat Ko, S. Tiong Ong, Seiji Yano	28
8	CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3) breakdown → 2018 ·Journal of Clinical Oncology ·Yi‐Long Wu, Myung‐Ju Ahn, Marina Chiara Garassino, Ji‐Youn Han, Nobuyuki Katakami, Hye Ryun Kim, Rachel Hodge, Paramjit Kaur, Andy Brown, Dana Ghiorghiu, Vassiliki A. Papadimitrakopoulou, Tony Mok	349
9	Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations 2018 ·Lung Cancer ·Ken Uchibori, Miyako Satouchi, Naoko Sueoka‐Aragane, Yoshiko Urata, Akemi Sato, Fumio Imamura, Takako Inoue, Motoko Tachihara, Kazuyuki Kobayashi, Nobuyuki Katakami, (unknown), Tomonori Hirashima, Kentaro Iwanaga, Masahide Mori, Keisuke Aoe, Satoshi Morita, Shunichi Negoro	13
10	Osimertinib With Ramucirumab in EGFR-mutated, T790M-positive Patients With Progression During EGFR-TKI Therapy: Phase Ib Study 2018 ·Clinical Lung Cancer ·Hiroaki Akamatsu, Yasuhiro Koh, Yuichi Ozawa, Daichi Fujimoto, Akito Hata, Nobuyuki Katakami, Keisuke Tomii, Toshio Shimokawa, Nobuyuki Yamamoto	12
11	Docetaxel Plus RAmucirumab With Primary Prophylactic Pegylated Granulocyte-ColONy Stimulating Factor Support for Elderly Patients With Advanced Non–small-cell Lung Cancer: A Multicenter Prospective Single Arm Phase II Trial: DRAGON Study (WJOG9416L) 2018 ·Clinical Lung Cancer ·Akito Hata, Nobuyuki Katakami, Mototsugu Shimokawa, Tetsuya Mitsudomi, Nobuyuki Yamamoto, Kazuhiko Nakagawa	2
12	MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR -mutant Lung Cancer 2017 ·Molecular Cancer Therapeutics ·Shigeki Nanjo, Sachiko Arai, Wei Wang, Shinji Takeuchi, Tadaaki Yamada, Akito Hata, Nobuyuki Katakami, Yasunori Okada, Seiji Yano	47
13	ONO-7643/anamorelin for the treatment of patients with non-small cell lung cancer and cachexia: results from phase 2 study with Japanese patients 2016 ·Annals of Oncology ·Junji Uchino, Nobuyuki Katakami, Takuma Yokoyama, Tateaki Naito, Masashi Kondo, Kenneth M. Yamada, (unknown), Kozo Yoshimori, Kazuhiro Sato, Yuichi Takiguchi, Koichi Takayama, K. Eguchi	1
14	Effect of Perioperative Pirfenidone Treatment in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis (West Japan Oncolgy Group 6711L): A Phase II Study 2015 ·CHEST Journal ·Takekazu Iwata, Ichiro Yoshino, Shigetoshi Yoshida, Norihiko Ikeda, Masahiro Tsuboi, Yuji Asato, Nobuyuki Katakami, Yoshinori Yamashita, Kazuhiro Sakamoto, Arata Azuma, Tae Iwasawa, Kazuyoshi Kuwano, Shuji Sakai, Kenzo Hiroshima, Junya Fukuoka, Kenichi Yoshimura, Hirohito Tada, Kazuhiko Nakagawa, Yoichi Nakanishi	1
15	A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study) 2015 ·Annals of Oncology ·Hiroshige Yoshioka, K. Azuma, Nobuyuki Yamamoto, Toshiaki Takahashi, Makoto Nishio, Nobuyuki Katakami, Myung‐Ju Ahn, T. Hirashima, Makoto Maemondo, (unknown), Mami Kurosaki, Shiro Akinaga, K. Park, C.-M. Tsai, Tomohide Tamura, Tetsuya Mitsudomi, Kazuhiko Nakagawa	89
16	Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial 2014 ·International Journal of Clinical Oncology ·Naohito Shimoyama, (unknown), Nobuyuki Katakami, (unknown), (unknown), (unknown), Megumi Shimoyama	8
17	A Randomized Phase III Study of Single-Agent Amrubicin Vs. Carboplatin/Etoposide in Elderly Patients With Extensive-Disease Small-Cell Lung Cancer 2013 ·Clinical Lung Cancer ·Ikuo Sekine, Hiroaki Okamoto, Takeshi Horai, Kazuhiko Nakagawa, Hironobu Ohmatsu, Akira Yokoyama, Nobuyuki Katakami, Masahiko Shibuya, Nagahiro Saijo, Masahiro Fukuoka	25
18	Final Analysis of Overall Survival (OS) in the IPASS, an International Multicenter Phase III Study on Gefitinib and Carboplatin/Paclitaxel for Treatment-na^\|^iuml;ve NSCLC Patients 2012 ·Haigan ·Miyako Satouchi, Yukito Ichinose, Yutaka Nishiwaki, Yuichiro Ohe, Nobuyuki Yamamoto, Nobuyuki Katakami, Kazuhiko Nakagawa, Katsuyuki Kiura, Haiyi Jiang, Tony Mok, Nagahiro Saijo, Masahiro Fukuoka	1
19	[Lung cancer with bone metastasis]. 2006 ·PubMed ·Nobuyuki Katakami	11
20	Postoperative complications after induction chemoradiotherapy in patients with non-small-cell lung cancer 2006 ·European Journal of Cardio-Thoracic Surgery ·Shiro Fujita, Nobuyuki Katakami, Yutaka Takahashi, (unknown), Akihiko Ikeda, Chiharu Tabata, Tadashi Mio, Michiaki Mishima	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact